Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 4/20 | 0.68 |
| ▸ | DRD4 | P21917 | 3/20 | 0.68 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.68 |
| ▸ | HTR7 | P34969 | 8/20 | 0.60 |
| ▸ | HTR1A | P08908 | 6/20 | 0.60 |
| ▸ | HTR2A | P28223 | 2/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2734416 | 0.93 | DRD2 (0.64) | DRD2DRD4SIGMAR1HTR7HTR1A | |
| SCHEMBL2733203 | 0.84 | DRD2 (0.51) | DRD2DRD4SIGMAR1HTR7HTR1A | |
| SCHEMBL11082045 | 0.83 | DRD2 (0.66) | DRD2DRD4SIGMAR1HTR7HTR1A | |
| Hydrochloric Acid SCHEMBL11084263 | 0.82 | DRD2 (0.64) | DRD2DRD4SIGMAR1HTR7HTR1A | |
| SCHEMBL793276 | 0.82 | DRD2 (0.60) | DRD2DRD4SIGMAR1HTR7HTR1A | |
| SCHEMBL18028056 | 0.81 | DRD2 (0.68) | DRD2DRD4SIGMAR1HTR7HTR1A | |
| SCHEMBL793052 | 0.81 | DRD2 (0.62) | DRD2DRD4SIGMAR1HTR7HTR1A | |
| SCHEMBL2734082 | 0.80 | HTR2A (0.57) | DRD2DRD4SIGMAR1HTR7HTR1A | |
| SCHEMBL2734699 | 0.80 | DRD2 (0.56) | DRD2DRD4SIGMAR1HTR7HTR1A | |
| SCHEMBL21678217 | 0.79 | DRD2 (0.57) | DRD2DRD4SIGMAR1HTR7HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8088778-B2 | Benzisoxazole piperazine compounds and methods of use thereof | HYPNION, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-8088778-B2 | Benzisoxazole piperazine compounds and methods of use thereof | HYPNION, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| EP-1877390-B1 | BENZISOXAZOLE PIPERAZINE COMPOUNDS AND METHODS OF USE THEREOF | HYPNION INC (US) | 2010-03-24 | — | — | EP | disclosed |
| US-20090163514-A1 | BENZISOXAZOLE PIPERAZINE COMPOUNDS AND METHODS OF USE THEREOF | COUGHLIN DANIEL | 2009-06-25 | — | — | US | disclosed |
| US-20090163514-A1 | BENZISOXAZOLE PIPERAZINE COMPOUNDS AND METHODS OF USE THEREOF | COUGHLIN DANIEL | 2009-06-25 | — | — | US | disclosed |
| US-7494998-B2 | Benzisoxazole piperazine compounds and methods of use thereof | HYPNION, INC. (US) | 2009-02-24 | — | — | US | disclosed |
| US-7494998-B2 | Benzisoxazole piperazine compounds and methods of use thereof | HYPNION, INC. (US) | 2009-02-24 | — | — | US | disclosed |
| US-20070004752-A1 | Benzisoxazole piperazine compounds and methods of use thereof | HYPNION, INC. | 2007-01-04 | — | — | US | disclosed |
| US-20070004752-A1 | Benzisoxazole piperazine compounds and methods of use thereof | HYPNION, INC. | 2007-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070004752-A1 | Benzisoxazole piperazine compounds and methods of use thereof | GABRA5, HCRTR2, HCRTR1 | DRD2 1869/4885DRD4 1256/4885SIGMAR1 693/4885 |
| US-20090163514-A1 | BENZISOXAZOLE PIPERAZINE COMPOUNDS AND METHODS OF USE THEREOF | GABRA5, HCRTR2, HCRTR1 | DRD2 1869/4885DRD4 1256/4885SIGMAR1 693/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.